This in vivo study tested the hypothesis that the modulation of acetylcholine (ACh) release by the M 1 muscarinic receptor (mAChR) in the neuromuscular junction of disused muscles may affect the tensions of the muscles during the neuromuscular monitoring of a rocuronium-induced neuromuscular block and compared the results with those obtained from normal muscles. A total of 20 C57BL/6 (wild-type) and 10 α7 knock out (α7KO) mice were used in this experiment. As a pre-experimental procedure, knee and ankle joints of right hind limbs were fixed by needle pinning at the 90° flexed position.
Summary
This in vivo study tested the hypothesis that the modulation of acetylcholine (ACh) release by the M 1 muscarinic receptor (mAChR) in the neuromuscular junction of disused muscles may affect the tensions of the muscles during the neuromuscular monitoring of a rocuronium-induced neuromuscular block and compared the results with those obtained from normal muscles. A total of 20 C57BL/6 (wild-type) and 10 α7 knock out (α7KO) mice were used in this experiment. As a pre-experimental procedure, knee and ankle joints of right hind limbs were fixed by needle pinning at the 90° flexed position.
After 2 weeks, the main experiment was performed. Both tendons of the tibialis anterior (TA) muscles were obtained, and the muscle tensions were recorded while the dose-responses of rocuronium were measured three times in the same mouse by the serial administration of pirenzepine (0, 0.001 and 0.01 μg/g). Weight losses were observed after 2 weeks of immobilization in both groups, and a decrease in the mass of TA muscles at the immobilized side was observed compared to those of the contralateral nonimmobilized side. Tension depression of the TA muscles at immobilized side of the α7KO group was faster than those of the wild-type group, but these differences decreased after the administration of pirenzepine. The tension depressions were similar regardless of the pirenzepine doses at the same side in the group. Tension depression may become more rapid in the α7 AChR-expressed disused muscles by the decreased release of ACh release upon neuronal firing by the blockade of facilitatory M 1 mAChR
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of adenosine, which is coreleased with ACh during neuronal stimulation at the synapse. 5, 6 On the other hand, when the frequency of evoked stimulation is high (> 50 Hz), the amount of adenosine is increased to levels capable of activating the facilitatory adenosine A 2A receptors which counteract the M 1 receptors and potentiates M 2 inhibitory receptors. [5] [6] [7] In normal innervated muscles, the mature form of nicotinic acetylcholine receptors (nAChRs) is present only in the neuromuscular postsynaptic area and is involved in neurotransmission. When the neuronal influence or activity is depressed, the γ subunit containing immature acetylcholine receptors (AChRs) are upregulated and expressed throughout the muscle membrane. [8] [9] [10] Neuronal AChRs containing five homometric α 7 -subunits, which were described previously only in the central nervous system, have more recently been described in the skeletal muscle after denervation only. 11 In some pathologic states, despite the intact innervations, the upregulation of immature or atypical AChRs occurs. Several studies have
shown that the disuse of a muscle leads to muscle atrophy and the de novo expression of immature AChRs throughout the muscle membrane, despite the presence of continued innervation.
12-14
The expression of the immature AChRs in the junctional area has been assumed to contribute to the resistance to non-depolarizing neuromuscular blocking agents during immobilization. Recently, there have been some reports of α7 nAChR expression after immobilization that revealed some important roles in the resistance to a neuromuscular blocking agent, such as rocuronium. 14, 15 In the clinical setting, there would be some changes on responses of neuromuscular blockade when the patient is in the long-time immobilized state, such as the cast of the part of the body or respiration therapy by the artificial respirator. In that situation, the modulation of the ACh release at the neuromuscular presynaptic side and thus the change of the concentration of ACh on the same neuronal firing would eventually affect the response of muscle on the nerve stimulation for neuromuscular monitoring. 3 This might be due to the mature form of nAChR, and α7 nAChR shows a different response to ACh or rocuronium. 14, 16, 17 As such, in this study, we tested the hypothesis that the reduction in ACh release by the modulation of M 1 mAChRs in the neuromuscular junction (especially those of the muscles after immobilization) could influence the tensions of the muscles during neuromuscular monitoring of rocuronium-induced neuromuscular block.
To accomplish this, mechanomyographic techniques together with pirenzepine in wild-type mice and mice genetically processed not to express the α7 subunits of the AChR (α7KO mice) were used. In addition, the hypothesis was tested in the immobilized tibialis anterior (TA) muscles of wild-type and αs7KO mice and compared with those in the contralateral normal ones.
| RE SULTS
Overall, decreases in bodyweight and TA muscle mass were observed during the immobilization period in all genotypes (Table 1) .
No significant differences in the bodyweight were observed between the wild-type and α7KO group. Weight losses were observed after 2 weeks of immobilization in both groups, and a decrease in the mass of TA muscles at the immobilized side was observed compared to those of contralateral non-immobilized side. After a 2-week period of immobilization, there was an average weight loss of 1.07 g and 1.81 g in the α7KO mice and wild-type mice, respectively. After completing the experiment, the TA muscles of both the immobilized and contralateral sides were harvested and their weights were compared. In all genotype mice, there were significant differences between the immobilized and the contralateral sides (P < 0.05).
The mean differences of weights of TA muscles were 12.2 mg and 9.29 mg in the α7KO mice and the wild-type mice, respectively (12.2 (4.57) vs 9.29 (5.65), P > 0.05).
Initially, the rocuronium dose-responses to the different pirenzepine doses at the same side of the same genotype were compared.
In the normal (contralateral) side of the wild-type mice, there were no significant changes in the rocuronium dose-responses by injecting and increasing pirenzepine. This was also observed in the immobilized side, but there was a decrease at low pirenzepine dose (0.01μg/g, PZP1) and an increase at high dose (0.1μg/g, PZP2). These findings were observed consistently in the α7KO mice ( Figure 1 ).
The rocuronium dose-responses were compared at immobilized and contralateral side of the wild-type mice, and the same comparison was performed in the α7KO mice. In the wild-type mice, there were significant differences between the immobilized and the contralateral sides at the initial stage, but these differences disappeared at PZP1 and PZP2 (Table 2, Figure 2b ,d,f). In α7KO mice, however, there were significant differences between both sides at the initial stage and these differences were maintained despite the injection of pirenzepine ( Data are expressed as the mean (SD). Wild, wild-type mice; α7KO, α7 knockout mice; BW initial, bodyweight at initial; BW immo, bodyweight at 2 weeks after immobilization; TA control, tibialis anterior muscle weight of the contralateral side; TA immo, tibialis anterior muscle weight of immobilized side. *P = 0.001 and 0.000 in wild and α7KO, respectively. **P = 0.000 and 0.001 in wild and α7KO, respectively.
TA B L E 1 Whole bodyweight at the initial and 2 weeks after immobilization, tibialis anterior muscle weight of immobilized side and contralateral side
We also compared data by the genotype at the initial, PZP1 and PZP2, respectively. At the initial and PZP1 stage, there were no significant differences in ED 50 and ED 95 between the wild-type and α7KO mice in the contralateral (normal) side. The ED 50 and ED 95 in each genotype were different at PZP2. But in the immobilized side, this difference pattern was quite different. At initial, there were significant differences in ED 50 and ED 95 between wild-type and α7KO mice. These differences disappeared when the pirenzepine was injected (Table 3) .
Tension depression of the TA muscles at the immobilized side of the α7KO group was significantly faster than those of the wild-type mice, but these differences were decreased after the administration of pirenzepine. Regardless of the administration of pirenzepine, no statistically significant differences on train-of-four (TOF) fade on the same side in the wild-type and α7KO group were observed (P > 0.05, Table 4 ). However, when compared with the immobilized and contralateral normal side, differences of TOF fade disappeared at the high dose of pirenzepine (PZP2) in the wild-type group (P = 0.014 and 0.001 in initial and PZP1, respectively, P = 0.103 in PZP2, Table 4 ).
| D ISCUSS I ON
In this in vivo experiment, the action modulation of M 1 mAChRs by the specific antagonist, pirenzepine, affected the dose-responses of rocuronium and the rocuronium-induced TOF fade when compared in the immobilized and normal muscles. In our previous ex vivo experiments, 3 it was demonstrated that the blockade of presynaptic M 1 mAChR with pirenzepine led to a lower requirement of rocuronium for a > 95% decrease in the twitch tension of the haemidiaphragm. In the present result, rocuronium needed for a >95% depression of the T1 twitch tension at the immobilized side was decreased in the PZP1 and to increased in PZP2 at the immobilized side of wild-type mice compared to the initial value. Although there were no significant differences between the initial, PZP1 and PZP2, these findings were comparable to those found at the previous ex vivo experiment. 3 The inclination for the decrease in rocuronium used in PZP1 might be due to the decrease in ACh release which is the blockade of the M 1 mAChR by pirenzepine. One limitation is that it is unclear whether the dose and incubation time of pirenzepine used in this in vivo experiment were appropriate. As there was no evidence or references of adoptable pirenzepine doses used in a similar study, Normally, α7 nAChR is involved in the neuroprotection of nicotine during stress-induced memory impairment and other beneficial effects. [19] [20] [21] On the other hand, in the neuromuscular physiology of anaesthesiology, the expression of α7 nAChR showed unusual, unexpected and undesirable effects, particularly on the induced neuromuscular blockade. 8, [22] [23] [24] [25] The α7 nAChR at the neuromuscular junction is expressed on the pathologic condition such as immobilization, inflammation or burn. The muscles at which the α7 nAChR is expressed showed resistance to the neuromuscular blocking agents such as rocuronium. The present study had several drawbacks and limitations.
Because the M 1 mAChR is a facilitatory autoreceptor, it is believed that repeated dose or increased doses of pirenzepine might further influence the decreased of rocuronium requirement for depressing T1 > 95%. On the other hand, by increasing the dose from 0.01 to 0.1 μg/g, pirenzepine showed quite opposite action. That is, the rocuronium dose appeared higher in PZP2 than in PZP1 in the wild-type mice. Although these changes were statistically insignificant, high dose of pirenzepine might have some reaction other than blocking M 1 mAChR. As is already known, specific antagonists for muscarinic receptors are not quite specific. 26 Therefore, it is important to find the adequate dose or reaction time is crucial. As described in Table 4 , there were statistically significant differences between the wild-type mice and α7KO mice in the contralateral side at the high dose of pirenzepine (PZP2). In the immobilized side, however, there was a significant difference at initial stage only. If these phenomena are true, this means that the blockade of M 1 mAChR and thus the decrease in ACh molecules at the neuromuscular synapse have some effect on the contralateral side at high doses.
In other words, the tensions of muscles in which the α7 nAChRs were expressed could be influenced more by the decrease in ACh at the synaptic junction. However, we did not examine the precise amount of ACh at each neuromuscular junction in this experiment;
only the functional data are compared. Therefore, a more discrete immunochemical investigation will be needed. Another limitation and drawback in the present experiment is that we extracted the data of PZP1 and PZP2 from the same mice. We allowed a Data are expressed as mean (SD). Wild, wild-type mice; α7KO, α7 knockout mice. The statistical significance was defined as the P < 0.05. PZP1, data obtained after injection of pirenzepine 0.01 μg/g; PZP2, data obtained after injection of pirenzepine 0.1 μg/g. Statistically significant differences were observed only at the initial period in the wild-type mice, but statistically significant differences were maintained at all times in the α7KO mice.
40-minute recovery time before the next session of the experiment was initiated, however, there is a lack of agreement that 40 minutes is a sufficient recovery time. This is the result obtained from our previous and pilot experiment. We considered full recovery to be when there was >95% recovery of T1 twitch tension and no tetanic fades by 50 Hz 5-s tetanic stimulation. These results were usually obtained within 30 minutes after the T1 twitch tensions were reappeared during the pilot study. We also confirmed that there were no differences in recovery indices (the time interval from 25% to 75% recovery of T1 twitch tension) by performing repeated doseresponse study of rocuronium after allowing 40-minute recovery time in the pilot study. We did not perform these procedures in the main experiment, however, fearing that such intense stimulations (50 Hz tetanic stimulation) might influence the next dose-response results. Instead, we allowed 10 minutes more for the recovery time in the main experiment. That is why we set the 40-minute recovery time in this experiment.
In conclusion, in the wild-type mice, resistance to neuromuscular blocking agents in the immobilized side was reduced when the M 1 mAChR was blocked by a specific antagonist, pirenzepine. In the α7KO mice, resistance to the neuromuscular blocking agents at the immobilized side was less than wild-type mice in the initial stage.
However, these differences between the immobilized and contralateral sides were maintained when the muscarinic M 1 receptor was blocked by specific antagonist, pirenzepine. The expression of α7 nAChR due to the disuse atrophy might have a different response to
Comparison of the progression of the T1 depression according to the side. In the α7KO mice, T1 depression of immobilized side and contralateral normal side at: (A) the initial stage; (C) PZP1; and (E) PZP2 was displayed; ( ) α7KO_control; ( ) α7KO_immo. In the wild-type mice, T1 depression of immobilized side and contralateral normal side at: (B) the initial stage; (D) PZP1; and (F) PZP2 was displayed; ( ) wild_control; ( ) wild_immo. The regression equation was set, which has a R 2 more than 0.8 and the constants representing their slopes were compared. Statistically significant differences in the slopes in the α7KO groups were observed throughout the entire period, but those of the wild-type group showed statistical significance only at the initial period. Initial, reference T1 depression; α7KO_immo, immobilized side of α7KO; α7KO_control, contralateral normal side of α7KO; Wild_immo, immobilized side of wild-type mice; Wild_ control; contralateral normal side of wildtype mice; PZP1, period at the injection of pirenzepine 0.01 μg/g; PZP2, period at the injection of pirenzepine 0.1 μg/g; ROC, cumulative doses of rocuronium the blockade of the presynaptic M 1 receptor which made diminished release of ACh upon neuronal stimulation. The sample size was estimated by considering the previous ex vivo study 3 and the preliminary pilot test. We considered that a sample Data are expressed as mean (SD). Statistical significance was defined as the P < 0.05. There were no statistical intergroup differences when comparing by time. α7KO, α7 knockout mice. PZP1, data obtained after injection of pirenzepine 0.01 μg/g; PZP2, data obtained after injection of pirenzepine 0.1 μg/g; Wild, wild-type mice. The next injection of boost dose was considered when the muscle twitch tension depression was less than 3% or inclined to increase compared with the previous twitch tension. Spontaneous recovery of the neuromuscular blockade was provided after confirming that there were no tibialis muscle responses to the sciatic nerve stimulation. Full recovery from the initial rocuronium dose-response study was confirmed by a T1 twitch tension, and TOFR was recovered at 95% of the initial value and these commonly took 30-40 minutes after a 95% blockade of the T1 twitch tension. After confirming the full recovery, pirenzepine 0.01 μg/g was injected via a jugular catheter and allowed 10 minutes for reaction time. Subsequently, another cumulative dose-response of rocuronium was administered, which was considered as the PZP1.
| MATERIAL S AND ME THODS

TA B L E 4
Finally, the data for PZP2 with 0.1 μg/g of pirenzepine were obtained with same sequence of PZP1. The present study protocol was summarized in Figure 3 .
For statistical analysis, the values are expressed as the mean (SD). The differences in bodyweights before and after immobilization and weights of TA muscles of immobilized and control sides were analysed using a paired-sample t test, and the differences in the bodyweights of each genotype were analysed using independent t test. The changes in percentage F I G U R E 3 Study diagram. A total of 20 C57BL/6 (wild-type) and 10 α7 knock out (α7KO) mice were used in this experiment. The entire experiment process was divided into two phases; Phase 1 is the preliminary process for right hindlimb immobilization and phase 2 is the main experiment. In the main experiment, the recovery time allowed was 40 minutes, and full recovery was considered when there was no tetanic fade by 50 Hz stimulation for 5 s. IVJ, internal jugular vein; TA, tibialis anterior muscle twitch depression (T1) were plotted and analysed by nonlinear regression using SPSS 13.0 Software (SPSS, Chicago, IL, USA 
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